157 related articles for article (PubMed ID: 28985276)
21. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Marso SP; Baeres FMM; Bain SC; Goldman B; Husain M; Nauck MA; Poulter NR; Pratley RE; Thomsen AB; Buse JB;
J Am Coll Cardiol; 2020 Mar; 75(10):1128-1141. PubMed ID: 32164886
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.
Alatorre CI; Hoogwerf BJ; Deeg MA; Nelson DR; Hunter TM; Ng WT; Rekhter MD
Curr Med Res Opin; 2018 Feb; 34(2):337-343. PubMed ID: 29065729
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
24. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
[TBL] [Abstract][Full Text] [Related]
26. Effect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients.
Kim YY; Lee JS; Kang HJ; Park SM
Sci Rep; 2018 Aug; 8(1):12190. PubMed ID: 30111867
[TBL] [Abstract][Full Text] [Related]
27. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R; Hadjadj S; Pasquet B; Wilson PW; Smith SC; Goto S; Tubach F; Marre M; Porath A; Krempf M; Bhatt DL; Steg PG
Int J Cardiol; 2013 Aug; 167(4):1380-4. PubMed ID: 22560911
[TBL] [Abstract][Full Text] [Related]
28. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.
Kohli P; Steg PG; Cannon CP; Smith SC; Eagle KA; Ohman EM; Alberts MJ; Hoffman E; Guo J; Simon T; Sorbets E; Goto S; Bhatt DL;
Am J Med; 2014 Jan; 127(1):53-60.e1. PubMed ID: 24280110
[TBL] [Abstract][Full Text] [Related]
29. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
Ferreira JP; Sharma A; Mehta C; Bakris G; Rossignol P; White WB; Zannad F
Clin Res Cardiol; 2021 Jul; 110(7):1006-1019. PubMed ID: 32789678
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins.
Neugebauer R; Schroeder EB; Reynolds K; Schmittdiel JA; Loes L; Dyer W; Desai JR; Vazquez-Benitez G; Ho PM; Anderson JP; Pimentel N; O'Connor PJ
JAMA Netw Open; 2020 Jan; 3(1):e1918554. PubMed ID: 31977057
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Cavender MA; Scirica BM; Raz I; Steg PG; McGuire DK; Leiter LA; Hirshberg B; Davidson J; Cahn A; Mosenzon O; Im K; Braunwald E; Bhatt DL
Am J Med; 2016 Mar; 129(3):340.e1-8. PubMed ID: 26524706
[TBL] [Abstract][Full Text] [Related]
32. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
[TBL] [Abstract][Full Text] [Related]
33. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
34. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.
Lawson CA; Jones PW; Teece L; Dunbar SB; Seferovic PM; Khunti K; Mamas M; Kadam UT
JACC Heart Fail; 2018 Jan; 6(1):18-26. PubMed ID: 29032131
[TBL] [Abstract][Full Text] [Related]
35. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
36. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
[TBL] [Abstract][Full Text] [Related]
37. Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source.
Ntaios G; Vemmos K; Lip GY; Koroboki E; Manios E; Vemmou A; Rodríguez-Campello A; Cuadrado-Godia E; Giralt-Steinhauer E; Arnao V; Caso V; Paciaroni M; Diez-Tejedor E; Fuentes B; Pérez Lucas J; Arauz A; Ameriso SF; Hawkes MA; Pertierra L; Gómez-Schneider M; Bandini F; Chavarria Cano B; Iglesias Mohedano AM; García Pastor A; Gil-Núñez A; Putaala J; Tatlisumak T; Barboza MA; Athanasakis G; Makaritsis K; Papavasileiou V
Stroke; 2016 Sep; 47(9):2278-85. PubMed ID: 27507859
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
Smith SM; Huo T; Delia Johnson B; Bittner V; Kelsey SF; Vido Thompson D; Noel Bairey Merz C; Pepine CJ; Cooper-Dehoff RM
J Am Heart Assoc; 2014 Feb; 3(1):e000660. PubMed ID: 24584740
[TBL] [Abstract][Full Text] [Related]
39. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
40. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
